Loading...
Loading...
ZNTL| Name | Value |
|---|---|
| Revenues | 40.6M |
| Cost of Revenue | 0.3M |
| Gross Profit | 40.2M |
| Operating Expense | 65.0M |
| Operating I/L | -24.8M |
| Other Income/Expense | 34.9M |
| Interest Income | 0.0M |
| Pretax | 10.2M |
| Income Tax Expense | 0.1M |
| Net Income/Loss | 10.1M |
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company specializing in the discovery and development of small molecule therapeutics for various cancers. The company's lead product candidates include ZN-c3, an inhibitor of WEE1 protein tyrosine kinase, in Phase 2 clinical trials for advanced solid tumors, and ZN-c5, an oral selective estrogen receptor degrader in Phase 1/2 clinical trials for advanced breast cancer treatment. Additionally, Zentalis is developing ZN-d5, a selective inhibitor of B-cell lymphoma 2, and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, both in clinical trials for non-Hodgkin's lymphoma and non-small cell lung cancer, respectively.
